The Food and Drug Administration (FDA) defines a rare disease as one that affects fewer than 200,000 people per year. For osteosarcoma, that rate is even smaller — about 1,000 new cases of osteosarcoma are diagnosed in the U.S each year. Children and teens represent about half of those cases.
Of course, osteosarcoma does not feel “rare” to families affected by it, as it is the most common primary bone cancer. More effective osteosarcoma therapeutic interventions are desperately needed.
Fernanda Arnaldez, MD, a Strategic Advisory Board member at the Osteosarcoma Institute (OSI) and a senior global product leader for AstraZeneca PLC, explains that despite the many complexities of drug development today, creative and collaborative solutions are on the horizon.